Nanomedicine to Overcome Current Parkinson's Treatment Liabilities: A Systematic Review

Neurotox Res. 2016 Nov;30(4):715-729. doi: 10.1007/s12640-016-9663-z. Epub 2016 Aug 31.

Abstract

Nanoparticles might be produced and manipulated to present a large spectrum of properties. The physicochemical features of the engineered nanomaterials confer to them different features, including the ability to cross the blood-brain barrier. The main objective of this review is to present the state-of-art research in nano manipulation concerning Parkinson's disease (PD). In the past few years, the association of drugs with nanoparticles solidly improved treatment outcomes. We systematically reviewed 28 studies, describing their potential contributions regarding the role of nanomedicine to increase the efficacy of known pharmacological strategies for PD treatment. Data from animal models resulted in the (i) improvement of pharmacological properties, (ii) more stable drug concentrations, (iii) longer half-live and (iv) attenuation of pharmacological adverse effects. As this approach is recent, with many of the described works being published less than 5 years ago, the expectancy is that this knowledge gives support to an improvement in the current clinical methods to the management of PD and other neurodegenerative diseases.

Keywords: Nanomedicine; Nanoparticles; Nanotechnology; Parkinson’s disease.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Animals
  • Antiparkinson Agents / administration & dosage*
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / pharmacology*
  • Clinical Trials as Topic
  • Humans
  • Nanomedicine*
  • Nanoparticles / administration & dosage
  • Nanoparticles / adverse effects
  • Parkinsonian Disorders / drug therapy*
  • Parkinsonian Disorders / metabolism

Substances

  • Antiparkinson Agents